Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Tissue Regenix Group PLC on Tuesday said it was aiming for longer-term growth as it reported a sharp reduction in its annual losses.
The Leeds, England-based medical devices company said pretax loss narrowed 41% to $1.7 million in 2023 from $2.8 million a year prior.
Revenue climbed 20% to $29.5 million from $24.5 million.
Cost of sales increased by 17% to $15.5 million from $13.2 million. Administrative expenses increased 8.8% to $14.4 million from $13.3 million.
Tissue Regenix proposed no dividend, unchanged from a year ago.
Looking ahead, Chief Executive Officer Daniel Lee said: ‘In 2024, we will begin some of the preliminary planning activities to build our phase 2 capacity expansion. In addition to our organic growth plans, we will continue to examine acquisition opportunities that would allow us to scale the business for additional longer-term growth.’
Tissue Regenix shares fell 2.5% to 66.80 pence each on Tuesday afternoon in London.
Copyright 2024 Alliance News Ltd. All Rights Reserved.